Exelixis initiated with a Buy at Jefferies Jefferies analyst Akash Tewari initiated coverage of Exelixis with a Buy rating and $28 price target. The analyst said that, despite recent clinical setbacks, Exelixis is one of the "most interesting" IP plays in SMID cap heading into next year. Tewari is bullish on Cabometyx's polymorph IP going out to 2030, which could add 30% to the stock, he said.Our Take: "On our trading list and we would buy at current levels. EXEL is currently undervalued."Horizon Therapeutics assumed with a Buy at JefferiesJefferies analyst Akash Tewari assumed coverage of Horizon Therapeutics with a Buy rating and $132 price target. The stock has further room to run as upside from the company's two products, Tepezza and Krystexxa, is not being appreciated by some investors and consensus, Tewari tells investors in a research note. The analyst believes Tepezza could have peak sales of $4.5B "given unappreciated upside."Our Take: "One of our biggest winners last year and this year. Keeps moving along/up. This is becoming a good core healthcare/drug group holding." $HZNP, Horizon Therapeutics Public Limited Company / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .